These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 21630086)
1. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086 [TBL] [Abstract][Full Text] [Related]
2. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814 [TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462 [TBL] [Abstract][Full Text] [Related]
4. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair. Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin. Alikarami F; Safa M; Faranoush M; Hayat P; Kazemi A Biomed Pharmacother; 2017 Oct; 94():1077-1093. PubMed ID: 28821159 [TBL] [Abstract][Full Text] [Related]
6. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells. Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565 [TBL] [Abstract][Full Text] [Related]
8. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair. Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644 [TBL] [Abstract][Full Text] [Related]
9. Targeting the DNA double strand break repair machinery in prostate cancer. Shaheen FS; Znojek P; Fisher A; Webster M; Plummer R; Gaughan L; Smith GC; Leung HY; Curtin NJ; Robson CN PLoS One; 2011; 6(5):e20311. PubMed ID: 21629734 [TBL] [Abstract][Full Text] [Related]
10. Radio-sensitization of human leukaemic MOLT-4 cells by DNA-dependent protein kinase inhibitor, NU7441. Tichy A; Durisova K; Salovska B; Pejchal J; Zarybnicka L; Vavrova J; Dye NA; Sinkorova Z Radiat Environ Biophys; 2014 Mar; 53(1):83-92. PubMed ID: 24100951 [TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation. Mitchell J; Smith GC; Curtin NJ Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1520-7. PubMed ID: 19931734 [TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655 [TBL] [Abstract][Full Text] [Related]
13. NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor. Yu L; Shang ZF; Hsu FM; Zhang Z; Tumati V; Lin YF; Chen BP; Saha D Oncotarget; 2015 Feb; 6(6):3848-60. PubMed ID: 25714019 [TBL] [Abstract][Full Text] [Related]
14. DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. Chua ML; Horn S; Somaiah N; Davies S; Gothard L; A'Hern R; Yarnold J; Rothkamm K Radiat Environ Biophys; 2014 May; 53(2):355-64. PubMed ID: 24622963 [TBL] [Abstract][Full Text] [Related]
15. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair. Gustafsson AS; Abramenkovs A; Stenerlöw B Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720 [TBL] [Abstract][Full Text] [Related]
16. Changes in the response of MCF-7 cells to ionizing radiation after the combination of ATM and DNA-PK inhibition. Ćmielová J; Havelek R; Vávrová J; Řezáčová M Med Oncol; 2015 May; 32(5):138. PubMed ID: 25801233 [TBL] [Abstract][Full Text] [Related]
17. Targeting DNA double strand break repair with hyperthermia and DNA-PKcs inhibition to enhance the effect of radiation treatment. van Oorschot B; Granata G; Di Franco S; Ten Cate R; Rodermond HM; Todaro M; Medema JP; Franken NA Oncotarget; 2016 Oct; 7(40):65504-65513. PubMed ID: 27602767 [TBL] [Abstract][Full Text] [Related]
18. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989 [TBL] [Abstract][Full Text] [Related]
19. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. Yu L; Tumati V; Tseng SF; Hsu FM; Kim DN; Hong D; Hsieh JT; Jacobs C; Kapur P; Saha D Neoplasia; 2012 Dec; 14(12):1203-12. PubMed ID: 23308052 [TBL] [Abstract][Full Text] [Related]
20. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]